Skip to main content

Table 1 Patient and disease characteristics

From: Mono-institutional phase 2 study of innovative Stereotactic Body RadioTherapy targeting PArtial Tumor HYpoxic (SBRT-PATHY) clonogenic cells in unresectable bulky non-small cell lung cancer: profound non-targeted effects by sparing peri-tumoral immune microenvironment

Characteristic:

No. (%)

p-value

SEX:

SBRT-PATHY

CHT

PALLIATIVE RT

Male

11 (55)

17 (85)

11 (55)

0.070

Female

9 (45)

3 (15)

9 (45)

AGE(years):

 Median/range

68.7/41–88

66.9/51–86

74.2/56–88

0.080

ECOG PERFORMANCE STATUS:

 0–1

12 (60)

15 (75)

8 (40)

0.078

 2–3

8 (40)

5 (25)

12 (60)

HISTOLOGY:

 Adenocarcinoma

8 (40)

12 (60)

8 (40)

0.340

 Squamous

12 (60)

8 (40)

8 (40)

0.340

 Other (mixed or no histology)

0 (0)

0 (0)

4 (20)

0.013

NSCLC STAGE:

 IIIB

12 (60)

7 (35)

11 (55)

0.247

 IV

8 (40)

13 (65)

9 (45)

TREATED BULKY SITE:

 Central

14 (70)

15 (75)

11 (55)

0.377

 Peripheral

6 (30)

5 (25)

9 (45)

0.380

 LLr

1 (5)

2 (10)

2 (10)

0.804

 LLl

6 (30)

2 (10)

5 (25)

0.279

 ULr

8 (40)

11 (55)

9 (45)

0.626

 ULl

5 (25)

5 (25)

4 (20)

0.911

UNRESCTABLE BULKY NSCLC:

 diameter mean/range (cm)

8.1/6–17

7.4/6–12

8.0/6–13

0.047

BULKY-RELATED SYMPTOMS:

 Dyspnea

15 (75)

11 (55)

14 (70)

0.377

 Cough

9 (45)

9 (45)

10 (50)

0.935

 Pain

12 (60)

6 (30)

10 (50)

0.153

 Haemoptysis

2 (10)

2 (10)

6 (30)

0.147

 Two or more symptoms

12 (60)

10 (50)

14 (70)

0.435

  1. Abbreviations: ECOG-Eastern Cooperative Oncology Group, NSCLC-non small cell lung cancer, SBRT-PATHY-SBRT PArtial Tumor irradiation of the HYpoxic segment,LLr-lower lobe right, LLl-lower lobe left, ULr-upper lobe right, ULl-upper lobe left, BTV-bystander tumor volume (hypoxic segment), CHT-chemotherapy, N.A.- not applicable